The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Abstract
Disease Overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR::ABL1 fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein. Frontline Therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first‐line treatment of newly diagnosed CML in chronic phase (CML‐CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. Salvage Therapy: For CML post failure on frontline therapy, second‐line options include second and third generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR::ABL1 mutational status. Patients who develop the T315I “gatekeeper” mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML‐CP and failure (due to resistance) of at least two TKIs, and for all patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on all TKIs can maintain long‐term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non‐TKI anti‐CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan and others).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationMahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citationMarin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationLeukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationKantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Self-citationCortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7162 · Cited by 495
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., Clark, R. E., Apperley, J. F., Milojkovic, D., Bua, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 476
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationConstitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
Jabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511592 · Cited by 395
Self-citationThe Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01111-2 · Cited by 351
Self-citationRéa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D.-W., Apperley, J. F., Abdo, A., et al. (2021) · Blood · doi:10.1182/blood.2020009984 · Cited by 342
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 341
Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0598 · Cited by 323
Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A., Berger, U., Hehlmann, R., Hiddemann, W., & Haferlach, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402329 · Cited by 314
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
Huang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
Self-citationCortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Self-citationHochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, et al. (2017) · Leukemia · doi:10.1038/leu.2017.63 · Cited by 293
Müller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 290
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationDarkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Hughes, T. P., Saglio, G., Kantarjian, H. M., Guilhot, F., Niederwieser, D., Rosti, G., Nakaseko, C., De Souza, C. A., Kalaycio, M. E., Meier, S., et al. (2014) · Blood · doi:10.1182/blood-2013-06-510396 · Cited by 257
Self-citationGiles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., Hughes, T. P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.181 · Cited by 251
Self-citationPrices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
Vokinger, K. N., Hwang, T. J., Grischott, T., Reichert, S., Tibau, A., Rosemann, T., & Kesselheim, A. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30139-x · Cited by 236
Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Issa, J., Garcia‐Manero, G., Rios, M. B., Shan, J., Andreeff, M., et al. (2003) · Cancer · doi:10.1002/cncr.11543 · Cited by 227
Self-citationCarpenter, P. A., Snyder, D., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2006-04-019836 · Cited by 226
Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 215
Self-citationBranford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832253 · Cited by 210
Cortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood · doi:10.1182/blood.2021012082 · Cited by 208
Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
Quintás-Cardama, A., Han, X., Kantarjian, H., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-09-180604 · Cited by 207
Self-citationBranford, S., Yeung, D. T., Parker, W. T., Roberts, N. D., Purins, L., Braley, J. A., Altamura, H. K., Yeoman, A. L., Georgievski, J., Jamison, B. A., et al. (2014) · Blood · doi:10.1182/blood-2014-03-566323 · Cited by 202
Shah, N. P., Guilhot, F., Cortes, J. E., Schiffer, C. A., le Coutre, P., Brümmendorf, T. H., Kantarjian, H. M., Hochhaus, A., Rousselot, P., Mohamed, H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532341 · Cited by 200
Self-citationWang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E., DiGiuseppe, J. A., Chen, Z., Kantarjian, H. M., Medeiros, L. J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690230 · Cited by 198
Self-citationApperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
Shah, N. P., Rousselot, P., Schiffer, C., Rea, D., Cortes, J. E., Milone, J., Mohamed, H., Healey, D., Kantarjian, H., Hochhaus, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24423 · Cited by 181
Self-citationRadich, J. P., Kopecky, K. J., Appelbaum, F. R., Kamel-Reid, S., Stock, W., Malnassy, G., Paietta, E., Wadleigh, M., Larson, R. A., Emanuel, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410688 · Cited by 174
Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170
Self-citationRole of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
Mandanas, R., Leibowitz, D., Gharehbaghi, K., Tauchi, T., Burgess, G., Miyazawa, K., Jayaram, H., & Boswell, H. (1993) · Blood · doi:10.1182/blood.v82.6.1838.1838 · Cited by 165
Jain, P., Kantarjian, H. M., Ghorab, A., Sasaki, K., Jabbour, E. J., Nogueras Gonzalez, G., Kanagal‐Shamanna, R., Issa, G. C., Garcia‐Manero, G., KC, D., et al. (2017) · Cancer · doi:10.1002/cncr.30864 · Cited by 160
Self-citationKantarjian, H., Schiffer, C., Jones, D., & Cortes, J. (2008) · Blood · doi:10.1182/blood-2007-09-110189 · Cited by 158
Self-citationGallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155
Self-citationPunish the parent not the progeny
Elrick, L. J., Jørgensen, H. G., Mountford, J. C., & Holyoake, T. L. (2004) · Blood · doi:10.1182/blood-2004-08-3373 · Cited by 148
Ross, D. M., Masszi, T., Gómez‐Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García‐Gutiérrez, V., Gattermann, N., le Coutre, P. D., Martino, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2604-x · Cited by 147
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Quintás‐Cardama, A., Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Thomas, D. M., Vidal‐Senmache, G., Wierda, W. G., Kornblau, S. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24257 · Cited by 144
Self-citationNaqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Self-citationJain, P., Kantarjian, H. M., Nazha, A., O'Brien, S. M., Jabbour, E. J., Romo, C. G., Pierce, S. A., Cárdenas-Turanzas, M., Verstovšek, S., Borthakur, G. M., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490128 · Cited by 134
Self-citationLee, S. J., Kukreja, M. K., Wang, T., Giralt, S. A., Szer, J., Arora, M., Woolfrey, A. E., Cervantes, F., Champlin, R. E., Gale, R. P., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141689 · Cited by 133
Oehler, V. G., Gooley, T. A., Snyder, D., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., et al. (2006) · Blood · doi:10.1182/blood-2006-06-031682 · Cited by 132
Nicolini, F. E., Basak, G. W., Kim, D., Olavarría, E., Pinilla-Ibarz, J. A., Apperley, J. F., Hughes, T. P., Niederwieser, D. W., Mauro, M. J., Chuah, C. T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30558 · Cited by 120
Self-citationWhy Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
Kantarjian, H. M., & Rajkumar, S. V. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.014 · Cited by 115
Self-citationWang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 113
Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., Dicato, M. A., & Diederich, M. F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.013 · Cited by 107
le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Blakesley, R. E., Shou, Y., Gallagher, N. J., Baccarani, M., Cortes, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.323 · Cited by 99
Self-citationNeelakantan, P., Gerrard, G., Lucas, C., Milojković, D., May, P. C., Wang, L., Paliompeis, C., Bua, M., Reid, A. G., Rezvani, K., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466037 · Cited by 95
Ochi, Y., Yoshida, K., Huang, Y., Kuo, M., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 94
Haddad, F., Sasaki, K., Issa, G. C., Garcia‐Manero, G., Ravandi, F., Kadia, T. M., Cortes, J. E., Konopleva, M. Y., Pemmaraju, N., Alvarado, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26550 · Cited by 87
Self-citationHochhaus, A., Gambacorti-Passerini, C. B., Abboud, C. N., Gjertsen, B. T., Brümmendorf, T. H., Smith, B. D., Ernst, T., Giraldo-Castellano, P., Olsson‐Strömberg, U., Saußele, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0915-9 · Cited by 85
Jain, P., Kantarjian, H. M., Alattar, M. L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00021-6 · Cited by 83
Self-citationJabbour, E. J., Branford, S., Saglio, G. N., Jones, D. M., Cortes, J. E., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.25717 · Cited by 82
Self-citationTestoni, N., Marzocchi, G., Luatti, S., Amabile, M., Baldazzi, C., Stacchini, M., Nanni, M., Rege‐Cambrin, G., Giugliano, E., Giussani, U., et al. (2009) · Blood · doi:10.1182/blood-2009-07-229864 · Cited by 81
Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Garcia‐Manero, G., Rios, M. B., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0693 · Cited by 78
Self-citationNaqvi, K., Jabbour, E. J., Skinner, J. A., Yilmaz, M. E., Ferrajoli, A., Bose, P., Thompson, P. A., Alvarado, Y., Jain, N., Takahashi, K., et al. (2018) · Cancer · doi:10.1002/cncr.31357 · Cited by 77
Self-citationJabbour, E. J., Cortes, J. E., Santos, F. P. D. S., Jones, D. M., O'Brien, S. M., Rondón, G., Popat, U., Giralt, S. A., Kebriaei, P., Jones, R. B., et al. (2010) · Blood · doi:10.1182/blood-2010-08-302679 · Cited by 76
Self-citationNteliopoulos, G., Bazeos, A., Claudiani, S., Gerrard, G., Curry, E. W., Szydlo, R., Alikian, M., Foong, H. E., Nikolakopoulou, Z., Loaiza, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.200220 · Cited by 73
Ko, T. K., Chuah, C. T. H., Huang, J. W. J., Ng, K.-P., & Ong, S. T. (2014) · Oncotarget · doi:10.18632/oncotarget.1925 · Cited by 71
Kantarjian, H. M., Shan, J., Jones, D. M., O'Brien, S. M., Rios, M. B., Jabbour, E. J., & Cortes, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6999 · Cited by 68
Self-citationHCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
Strati, P., Kantarjian, H. M., Thomas, D. A., O'Brien, S. M., Konoplev, S. N., Jorgensen, J. L., Luthra, R., Abruzzo, L. V., Jabbour, E. J., Quintás‐Cardama, A., et al. (2013) · Cancer · doi:10.1002/cncr.28433 · Cited by 66
Self-citationJabbour, E. J., Cortes, J. E., Kantarjian, H. M., Giralt, S., Andersson, B. S., Giles, F. J., Shpall, E. J., Kebriaei, P., Champlin, R. E., & de Lima, M. (2007) · Cancer · doi:10.1002/cncr.22778 · Cited by 64
Self-citationCopland, M., Slade, D., McIlroy, G., Horne, G. A., Byrne, J., Rothwell, K., Brock, K., de Lavallade, H., Craddock, C., Clark, R. E., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00370-7 · Cited by 64
Murai, K., Ureshino, H., Kumagai, T., Tanaka, H., Nishiwaki, K., Wakita, S., Inokuchi, K., Fukushima, T., Yoshida, C., Uoshima, N., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00333-1 · Cited by 63
Quintás‐Cardama, A., Cortes, J. E., O'Brien, S. M., Ravandi, F., Borthakur, G. M., Liu, D., Bleickardt, E. W., Chen, T., & Kantarjian, H. M. (2009) · Cancer · doi:10.1002/cncr.24325 · Cited by 62
Self-citationMolecular monitoring in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23427 · Cited by 59
Self-citationShih, Y. T., Cortes, J. E., & Kantarjian, H. M. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30087-0 · Cited by 58
Self-citationCortes, J. E., Jiang, Q., Wang, J., Weng, J., Zhu, H., Liu, X., Hochhaus, A., Kim, D., Radich, J. P., Savona, M. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0805-1 · Cited by 58
Ohanian, M. N., Kantarjian, H. M., Quintás‐Cardama, A., Jabbour, E. J., Abruzzo, L. V., Verstovšek, S., Borthakur, G. M., Ravandi, F., Garcia‐Manero, G., Champlin, R. E., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.08.008 · Cited by 56
Self-citationCortes, J. E., Gambacorti-Passerini, C. B., Kim, D., Kantarjian, H. M., Lipton, J. H., Lahoti, A., Talpaz, M., Matczak, E. M., Barry, E. V., Leip, E. P., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.001 · Cited by 54
Self-citationCortes, J. E., Hughes, T. P., Mauro, M. J., Hochhaus, A., Réa, D., Goh, Y. T., Janssen, J. J. W. M., Steegmann, J. L., Heinrich, M. C., Talpaz, M., et al. (2020) · Blood · doi:10.1182/blood-2020-139677 · Cited by 53
Marin, D., Ibrahim, A., Lucas, C., Gerrard, G., Wang, L., Szydlo, R., Clark, R., Apperley, J., Milojkovic, D., Bua, M., et al. (2012) · UCL Discovery (University College London) · Cited by 50
Abaza, Y., Kantarjian, H. M., Alwash, Y., Borthakur, G. M., Champlin, R. E., Kadia, T. M., Garcia‐Manero, G., Daver, N. G., Ravandi, F., Verstovšek, S., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25939 · Cited by 47
Self-citationHughes, T. P., Leber, B. F., Cervantes, F., Spector, N., Pasqüini, R., Clementino, N., Schwarer, A. P., Dorlhiac‐Llacer, P. E., Mahon, F., Réa, D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.247 · Cited by 44
Cortes, J. E., Souza, C. A. D., Ayala, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30167-3 · Cited by 42
Kantarjian, H. M., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9176 · Cited by 40
Self-citationYamamoto, C., Nakashima, H., Ikeda, T., Kawaguchi, S., Toda, Y., Ito, S., Mashima, K., Nagayama, T., Umino, K., Minakata, D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000745 · Cited by 38
Nazha, A., Kantarjian, H. M., Jain, P., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090282 · Cited by 35
Self-citationLong‐term results of frontline dasatinib in chronic myeloid leukemia
Maiti, A., Cortes, J. E., Patel, K. P., Masárová, L., Borthakur, G. M., Ravandi, F., Verstovšek, S., Ferrajoli, A., Estrov, Z. E., Garcia‐Manero, G., et al. (2020) · Cancer · doi:10.1002/cncr.32627 · Cited by 34
Self-citationHigh cancer drug prices 4 years later—Progress and prospects
Kantarjian, H. M., & Patel, Y. B. (2017) · Cancer · doi:10.1002/cncr.30545 · Cited by 32
Self-citationBrümmendorf, T. H., Cortes, J. E., Milojković, D., Gambacorti-Passerini, C. B., Clark, R. E., le Coutre, P. D., García‐Gutiérrez, V., Chuah, C. T. H., Kota, V. K., Lipton, J. H., et al. (2020) · Blood · doi:10.1182/blood-2020-137393 · Cited by 31
O’Brien, S. G., Hedgley, C. A., Adams, S., Foroni, L., Apperley, J. F., Holyoake, T. L., Pocock, C., Byrne, J., Seeley, L. M., Osborne, W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.517.517 · Cited by 26
Cortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., Shelat, S. G., Li, L., & Jabbour, E. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7051 · Cited by 23
Self-citationMasárová, L., Cortes, J. E., Patel, K. P., O'Brien, S. M., Nogueras‐González, G. M., Konopleva, M. Y., Verstovšek, S., Garcia‐Manero, G., Ferrajoli, A., Kadia, T. M., et al. (2020) · Cancer · doi:10.1002/cncr.32623 · Cited by 20
Self-citationHaddad, F., Kantarjian, H. M., Jabbour, E. J., Issa, G. C., Garcia‐Manero, G., Ravandi, F., Konopleva, M. Y., Ferrajoli, A., Kadia, T. M., Pemmaraju, N., et al. (2021) · Blood · doi:10.1182/blood-2021-154380 · Cited by 15
Self-citationJabbour, E. J., Deininger, M. W., Abruzzese, E., Apperley, J. F., Cortes, J. E., Chuah, C. T. H., DeAngelo, D. J., DiPersio, J. F., Hochhaus, A., Lipton, J. H., et al. (2021) · Blood · doi:10.1182/blood-2021-146175 · Cited by 15
Self-citationQian, J., Shi, D., Li, Z., Qin, Y., Zhao, T., Liu, B., Chen, Z., Niu, Q., Men, L., Wang, H., et al. (2021) · Blood · doi:10.1182/blood-2021-153065 · Cited by 14
Shaya, J. A., Pettit, K. M., Kandarpa, M., Bixby, D. L., Mercer, J., & Talpaz, M. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.001 · Cited by 13
Rousselot, P. H., Loiseau, C., Delord, M., Besson, C., Cayuela, J., & Spentchian, M. (2019) · Blood · doi:10.1182/blood-2019-129919 · Cited by 9
Monitoring and defining early response: Where to draw the line?
Branford, S. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.10.006 · Cited by 6
Réa, D., Hochhaus, A., Mauro, M. J., Minami, Y., Галактионовна, Л. Е., Волошин, С. В., Turkina, A., Kim, D.-W., Apperley, J. F., Cortes, J. E., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000843512.62237.dc · Cited by 5
Cited by
Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26852 · Cited by 22
Self-citationCortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02592-9 · Cited by 16
Metadata
- Authors
- Jabbour, E., & Kantarjian, H.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2022-07-06
- Volume
- 97
- Issue
- 9
- Pages
- 1236-1256
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W4283447987
- Cited by
- 281
- References
- 133
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.